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AbstrAct
The purpose of this study was to investigate the clinical activity, safety and 
predictive biomarkers of dacomitinib, an irreversible pan-HER inhibitor, in patients 
with recurrent or metastatic esophageal squamous cell carcinoma (R/M-ESCC). 
Patients, whose diseases were not amenable to curative treatment and had progressed 
on platinum-based chemotherapy, were treated with dacomitinib 45mg/day. The 
primary endpoint was objective response rate by RECISTv 1.1. Predictive biomarker 
analyses included the characterization of somatic mutations and gene expression 
using the Ion Torrent AmpliSeq Cancer Hotspot Panel and Nanostring nCounter, and 
investigation of their relationship with clinical outcomes. Of the 48 evaluable patients, 
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IntroductIon
Esophageal cancer is the sixth most common cause 
of cancer deaths worldwide [1]. Two major histologic 
subtypes of esophageal cancer, adenocarcinoma and 
squamous cell carcinoma, have different epidemiology 
and risk factors. Esophageal adenocarcinoma, which is 
associated with gastroesophageal reflux and obesity, has 
become more common in Western countries. In many 
Asian countries, however, esophageal squamous cell 
carcinoma (ESCC), of which risk factors are smoking and 
alcohol abuse, represents the most common esophageal 
cancer [2]. 
Despite modest improvements in survival with 
multimodal therapy, the prognosis for patients with 
locally advanced ESCC remains dismal, with a 5-year 
survival rate below 30%. The majority of patients 
with locally advanced disease will develop both local 
and distant recurrences and will die within a year after 
recurrence. Platinum-based chemotherapy remains the 
backbone of treatment in recurrent or metastatic ESCC 
(R/M-ESCC). However, clinical benefit of the platinum-
based chemotherapy is typically modest with reported 
objective response rate (ORR) of 20 to 35% and median 
overall survival (OS) of 7 to 9 months [3, 4]. Although 
a number of patients who progress after platinum-based 
chemotherapy may still be fit for second-line treatment, 
no treatments are available with proven efficacy for these 
patients. 
Over the past decade, molecularly targeted therapies, 
which block important oncogenic pathways, have made 
remarkable progress, especially in epidermal growth 
factor receptor (EGFR) mutation-positive non-small cell 
lung cancer (NSCLC). In contrast, there have been only 
a few clinical trials with targeted agents in R/M-ESCC. 
Moreover, despite potential clinical and/or biological 
heterogeneity, most clinical trials included both squamous 
and adenocarcinoma histologies without the identified 
druggable target that showed clinical benefit. Given a high 
rate of older age and/or comorbidities, there is a pressing 
need for biomarker-directed targeted therapy to improve 
the efficacy and tolerability in ESCC patients. 
The EGFR family (EGFR/ErbB1/HER1, ErbB2/
HER2, ErbB3/HER3, ErbB4/HER4) plays an essential 
role in mediating cell proliferation, angiogenesis, and 
metastasis. Therefore, it has become an important 
therapeutic target in NSCLC, breast cancer and head and 
neck squamous cell carcinoma. EGFR overexpression and 
amplification was frequently observed in ESCC and was 
correlated with advanced tumor stage and poor prognosis 
[5]. Moreover, overexpression of HER2-4 has been 
reported to be present in 30% to 80% of ESCC[6, 7]. 
In this context, there is a strong rationale for 
investigation of biologic agents targeting EGFR family in 
ESCC. Gefitinib and erlotinib are EGFR-tyrosine kinase 
inhibitors (TKIs) which selectively block EGFR signaling 
through competitive reversible binding at intracellular 
EGFR-TK domain. In a small phase II study, gefitinib 
showed limited activity (ORR, 2.8%; OS, 164 days) in 
second-line treatment of advanced esophageal cancer [8]. 
Of note, a higher rate of disease control with gefitinib was 
observed in female patients with ESCC and high EGFR 
expression. Erlotinib also exhibited higher ORR (15% vs. 
0%) and longer time to progression (3.3 vs. 1.6 months) 
in ESCC, compared with adenocarcinoma [9]. Based on 
these studies, further evaluation of EGFR-targeted therapy 
in advanced ESCC is strongly warranted. 
Dacomitinib (PF-00299804) is a potent, irreversible 
pan-HER inhibitor. Dacomitinib demonstrated 
encouraging clinical activity against EGFR mutation-
positive NSCLC and head and neck squamous cell 
carcinomas [10, 11]. Because EGFR family members act 
together via hetero- and homodimerization to activate 
oncogenic signaling pathways, combined inhibition of all 
EGFR family kinases may have more potent antitumor 
activity than the EGFR inhibition alone.
This phase II study (ClinicalTrials.gov identifier 
NCT01608022) assessed the efficacy, safety, and 
predictive biomarkers of dacomitinib in patients with 
R/M-ESCC who progressed after 1 or 2 chemotherapy 
regimens.
6 (12.5%) achieved partial responses and 29 (60.4%) had stable disease. The median 
response duration was 7.1 months. The median progression free survival (PFS) and 
overall survival (OS) was 3.3 months (95% CI, 2.4-4.3 months) and 6.4 months (95% 
CI, 4.4-8.4 months). Adverse events were mostly grade 1-2. Gene set enrichment 
analysis revealed that ERBB signaling pathway is significantly enriched in patients 
with PFS ≥4 months (n = 12) than PFS < 4 months (n = 21) (p < 0.001). Upregulation 
of ERBB signaling pathway was significantly associated with longer PFS (5.0 vs. 2.9 
months, P = 0.016) and OS (10.0 vs. 4.8 months, P = 0.022). The most frequent 
mutations were TP53 (61%) followed by CDKN2A (8%), MLH1 (8%), FLT3 (8%) 
and EGFR (8%). Dacomitinib demonstrated clinical efficacy with manageable toxicity 
in platinum-failed R/M-ESCC. Screening of ERBB pathway-related gene expression 
profiles may help identify patients who are most likely benefit from dacomitinib.
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table 1: baseline patient characteristics (n=49)
Characteristics No. of patients %
Age, years
Median, range 64 47-83
Sex
Male 48 98.0
Female 1 2.0
Performance status
0 7 14.2
1 38 77.6
2 4 8.2
Smoking status
Never-smoker 6 12.2
Former smoker 31 63.3
Current smoker 12 24.5
Smoking dosage
Median, range 20 (0-80)
Stage at diagnoses
I 6 12.2
II 11 22.5
III 20 40.8
IV 12 24.5
Disease status at study entry
Locoregional 18 36.7
Distant 13 26.5
Both 18 36.7
Previous treatment
Chemotherapy alone 13 26.5
Surgery + CT 13 26.5
Radiation + CT 17 34.7
Surgery + RT + CT 6 12.2
No. of prior chemotherapy regimen*
1 33 67.3
2 16 32.7
Prior chemotherapy regimen
Cisplatin alone 2 4.1
PF regimen 38 77.6
DP regimen 23 46.9
TPF regimen 2 4.1
Abbreviations: PF, cisplatin and 5-fluorouracil; DP, docetaxel and cisplatin; TPF, docetaxel, cisplatin and fluorouracil; RT, 
radiotherapy; CT, chemotherapy
*Chemotherapy given as adjuvant, part of multimodality treatment, or palliative treatment
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results
Patient characteristics
Between June 2012 to Aug 2013, a total of 49 
patients were enrolled into the study and were received at 
least one dose of dacomitinib. The patient characteristics 
are listed in Table 1. The median age was 64 years. 
Majority of patients were male and ECOG PS 0-1. 
Approximately 40% of the patients had both locoregional 
and distant diseases in at least 3 organ sites. Two thirds 
of patients (73.5%) had received two or more treatment 
modalities including surgery, chemotherapy, and 
radiotherapy prior to enrollment. Thirty-three patients 
(67.3%) received dacomitinib as second-line treatment 
and sixteen patients (32.7%) received as third-line 
chemotherapy. Approximately 60% of patients received 
5-fluorouracil and cisplatin prior to enrollment. The 
median time from initial diagnosis to the study enrollment 
was 10.3 months (range, 2.5 to 93 months).
Efficacy and treatment delivery
Response was not evaluable in one patient 
because of rapid clinical deterioration. The waterfall 
plot of maximum percentage changes from baseline for 
48 evaluable patients are shown in Figure 1. Of the 48 
evaluable patients, 6 patients (12.5%) had confirmed 
partial responses (Table 2). The six patients had PRs 
lasting 16.6+, 8.5, 7.1, 4.1, 2.0, 2.0 months, respectively, 
with the median response duration of 7.1 months. Twenty-
nine patients (60.4%) had stable disease and 13 patients 
(27.1%) experienced progression. The 8-week DCR was 
72.9 % (35/48). The median number of treatment cycle 
was 3 (range, 1-21) and the median treatment duration 
is 2.9 months (range, 0.6-21.6 months) with 9 patients 
(18.4%) treated for longer than 6 months. Reasons for 
treatment discontinuation were disease progression (n 
= 43, 87.8%), refusal of the patient because of adverse 
events (n = 3, 6.1%), and other medical conditions (n = 2, 
4.1%, infection). 
With a median follow-up of 12.1 months, the median 
PFS was 3.3 months (95% CI, 2.4-4.3 months). Fifteen 
patients (30.6%) were progression free at 4 months and 
were considered to achieve clinical benefit (Supplementary 
Figure 1A). The median OS was 6.4 months (95% CI, 
4.4-8.4 months) and 5 patients (10.2%) were alive at 1 
year (Supplementary Figure 1B). There was no significant 
difference in PFS and OS for performance status, initial 
stage at study entry, and body weight.
Adverse events
All the 49 patients were assessed for treatment-
related AEs (Table 3). AEs were mostly grade 1 to 2 and 
easily manageable. The most common AEs were diarrhea 
(69.4%), acneiform rash (67.3%) and mucositis (61.2%). 
Treatment-related grade 3 AEs occurred in 13 patients 
Figure 1: Waterfall plot of maximum percentage changes from baseline in sum of the largest diameter of target lesions 
(n=48).
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Table 2: Best response by RECIST 1.1 (N=48)
characteristic no. of Patients %
Best response
Complete response 0 0
Partial response (confirmed) 6 12.5
Stable disease 29 60.4
Progressive disease 13 27.1
Nonevaluable* 1 NA
Objective response rate (95% CI)    12.5% (5.9 to 24.2)
*Response was not evaluable in one patient because of rapid clinical deterioration
NA: not available 
Figure 2: A. GSEA enrichment plot of KEGG ERBB pathway genes. Genes in the ERBB signaling pathway showed significant 
enrichment in patients with clinical benefit (PFS ≥4 months) vs. patients with non-CB (PFS <4 months). The top portion of the figure plots 
the enrichment scores (ES) for each gene, whereas the bottom portion of the plot shows the value of the ranking metric moving down the 
list of ranked genes. The table enumerates the genes in the ERBB pathway for which a majority of probe sets were significantly enriched 
and upregulated in in patients with clinical benefit vs. patients with non-clinical benefit. b. Hierarchical cluster analysis of gene expression 
(n= 33). Samples were represented in descending order of PFS (from left to right). The first row indicated subgroup according to gene 
expression profiles (cluster 1 vs. cluster 2). The second row indicated subgroup according to clinical benefit to dacomitinib (PFS <4 months 
vs. PFS ≥ 4 months). 
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mainly acneiform rash in 5 (10.2%), mucositis in 2 (4.1%), 
and diarrhea in 2 (4.1%). Nineteen patients (38.8%) had 
treatment interruption due to toxicity and 14 (28.6%) had 
a dose reduction. Of those 14 patients, 11 (78.6%) required 
a dose reduction to 30mg daily and 3 (21.4%) required a 
dose reduction to 15 mg daily. 
Association of gene expressions with clinical 
outcomes
Gene expression profiles were available in 33 
(67.3%; Figure 2, Supplementary Table 1). The GSEA 
of gene expression profiles against Kyoto Encyclopedia 
Table 3: Treatment-related adverse events (N=49)
Toxicity All grades Grade 3
No. of patients % No. of patients %
Hematologic
Anemia 6 12.2 0 0
Nonhematologic
Diarrhea 34 69.4 2 4.1
Acneiform rash 33 67.3 5 10.2
Mucositis 30 61.2 2 4.1
Anorexia 24 49.0 1 2.0
Paronychia 11 23.5 0 0
Fatigue 8 16.3 0 0
Hand-foot syndrome 7 14.3 0 0
Creatinine elevation 4 8.2 1 2.0
Nausea 4 8.2 0 0
Myalgia 3 6.1 0 0
Dyspepsia 2 4.1 0 0
Dysphagia 2 4.1 0 0
Dry skin 2 4.1 0 0
Hemoptysis 1 2.0 1 2.0
AST elevation 1 2.0 1 2.0
ALT elevation 1 2.0 0 0
Vomiting 1 2.0 0 0
Arthralgia 1 2.0 0 0
Neuropathy 1 2.0 0 0
Dry eye 1 2.0 0 0
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of Genes and Genomes (KEGG) database was used 
to identify differentially enriched signaling pathway 
between patients with CB and non-CB on dacomitinib. 
Among the 27 upregulated human KEGG pathway gene 
sets, this approach identified 20 significant pathways at 
25% false discovery rate (FDR) level (Supplementary 
Table 1). Notable among them were the ERBB signaling 
pathway, given the biologic and predictive potential of 
ERBB pathway activation. The pathway enrichment plot 
and expression profiles of a subset of genes contributing 
significantly to the core enrichment in patients with CB 
were shown in Figure 2A and 2B. Of the 87 pathway-
affiliated genes of the ERBB pathway, 20 genes 
including ERBB4, EGF, EGFR, AKT1, and MAPK10 
were differentially expressed between patients with CB 
(n = 12) and non-CB (n = 21) (P < 0.001; Figure 2B). 
Hierarchical cluster analysis demonstrated 33 tumors 
could be classified into 2 clusters, each with distinctive 
expression pattern of ERBB pathway genes. All but one 
patient showing CB on dacomitinib belonged to cluster 1 
with upregulation of ERBB pathway genes. 
Notably, patients with upregulated ERBB pathway 
(cluster 1, n = 14) showed significantly longer PFS (5.0 
vs. 2.9 months, P = 0.016) and OS (10.0 vs 4.8 months, 
P = 0.022), compared to those without (cluster 2, n = 19) 
(Figure 3A, 3B). Furthermore, among the 32 evaluable 
case, patients with upregulated ERBB pathway (3 out 
of 14) tended to have higher ORR (21.4% vs. 5.6%, P = 
0.18), compared to those without (1 out of 18).
Association of somatic mutations with clinical 
outcomes
Somatic mutation results were available in 36 
patients (73.5%; Figure 4). Median sequencing depth 
in target regions was 730X. Overall, we identified 44 
somatic coding single nucleotide variants (SNVs) and 
small insertions/deletions (indels). The full list of somatic 
mutations is provided in Supplementary Table 2. The list 
of the 13 recurrently mutated genes in two or more tumors 
or well-known driver cancer genes involved in 5 important 
oncogenic pathways (cell cycle, PI3K/mTOR, receptor 
tyrosine kinase, WNT and metabolism) is presented in 
Figure 4. The most frequently mutated genes were TP53 
(61%) followed by CDKN2A (8%), MLH1 (8%), FLT3 
(8%), and EGFR (8%). EGFR mutations were found in 3 
patients (1 CB, 2 non-CB). Interestingly, all these EGFR 
mutations were not classic drug-sensitive exon 19 and 21 
mutations frequently identified in NSCLC, but atypical 
exon 20 mutations (V765M, C775Y, and G810D). No 
specific mutation appeared to be enriched in patients with 
CB.
Association of ERBB expression and sensitivity to 
dacomitinib
To evaluate the association of drug sensitivity with 
ERBB gene expression, we performed detail analysis 
of cell viability assay with dacomitinib. Three ESCC 
cell lines with various levels of EGFR were treated 
with dacomitinib. Significant inhibition of tumor cell 
growth by dacomitinib was found in cells with high-
Figure 3: Kaplan-Meier estimates of A. progression-free survival and b. overall survival for patients with upregulated ERBB 
pathway (cluster 1) compared to those without (cluster 2).
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EGFR expression (TE2 and TE3) in comparison to that 
against low-EGFR expressing HCE4 (Figure 5A-5C). The 
clonogenicity was deceased in TE2 and TE3 cell lines, but 
not in HCE4. To determine dacomitinib mediated down-
regulation, we assessed phosphorylation in the EGFR 
signaling pathway. Dacomitinib dramatically reduced 
phosphorylated EGFR and AKT, and ERK in TE3 and 
TE2 ESCC cell lines whereas no change was detected in 
Table 4: Significant KEGG gene set enriched in patients with clinical benefit to dacomitinib 
Gene set size es nes Nominalp value
Fdr
q value
rank
at Max
1 KEGG_JAK_STAT_SIGNLING_PATHWAY 19 0.71 2.07 0.000 0.000 37
2 KEGG_APOPTOSIS 17 0.68 2.04 0.000 0.000 24
3 KEGG_NEUROTROPHIN_PATHWAY 19 0.67 1.99 0.000 0.000 19
4 KEGG_ENDOCYTOSIS 17 0.75 1.90 0.000 0.002 41
5 KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 30 0.65 1.90 0.001 0.002 41
6 KEGG_ERBB_SIGNALING_PATHWAY 20 0.63 1.88 0.000 0.002 42
7 KEGG_T-CELL_RECEPTOR_SIGNLING_PATHWAY 15 0.61 1.87 0.000 0.002 33
8 KEGG_REGULATION_OF_ACTIN_CYTOSKELETON 20 0.59 1.83 0.001 0.003 40
9 KEGG_PATHWAYS_IN_CANCER 85 0.49 1.81 0.000 0.004 57
10 KEGG_MELANOMA 29 0.52 1.78 0.000 0.005 49
11 KEGG_PROSTATE_CANCER 31 0.50 1.78 0.000 0.005 69
12 KEGG_GLIOMA 25 0.51 1.78 0.000 0.004 49
13 KEGG_CELL_CYCLE 28 0.51 1.76 0.002 0.006 69
14 KEGG_ACUTE _MYELOID_LEUKEMIA 18 0.51 1.70 0.005 0.010 26
15 KEGG_PANCREATIC_CANCER 25 0.49 1.68 0.001 0.011 49
16 KEGG_P53 _SIGNALING_PATHWAY 20 0.51 1.67 0.001 0.012 77
17 KEGG_MAPK_SIGNALING_PATHWAY 36 0.52 1.67 0.005 0.012 42
18 KEGG_NON_SMALL_CELL_LUNG_CANCER 20 0.51 1.63 0.008 0.019 49
19 KEGG_FOCAL_ADHESION 31 0.50 1.60 0.037 0.023 62
20 KEGG_ENDOMETRIAL_CANCER 19 0.50 1.59 0.012 0.024 40
KEGG, Kyoto Encyclopedia of Genes and Genomes; ES, Enrichment score; NES, Normalized enrichment score
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Figure 4: Somatic mutation profiles between patients with non-clinical benefit (PFS <4 months; n = 25) and patients 
with clinical benefit (PFS ≥4 months; n = 11). Samples were represented in descending order of PFS. Gene symbol, frequency of 
mutations and involved pathways were shown in the left panel.
Figure 5: The anti-tumor efficacy of dacomitinib in ESCC cell lines with different EGFR expression. The viability of TE2, 
TE3, and HCE4 cell lines were measured by proliferation A. and clonogenic assay b.. The relative cell viability (%) and colonies represents 
the percent growth as compared to the control group (no treatment). c. Expression of EGFR was analyzed by quantitative real-time PCR. 
Expression of each EGFR mRNA is presented as relative to the mRNA expression of the internal control gene β-actin. d. The protein levels 
were measured by Western blot after 2 h treatment of dacomitinib.
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HCE4 cell line (Figure 5D). Taken together, high EGFR 
expression was associated with sensitivity to dacomitinib 
in ESCC cell lines.
dIscussIon
Because the majority of R/M-ESCC patients will 
not benefit from second-line chemotherapy but will 
nevertheless be subjected to potentially life-threatening 
toxicities,[12] the development of effective targeted 
therapy with predictive biomarker is of vital importance 
in this population with poor prognosis. Nevertheless, 
therapeutic advances in R/M-ESCC significantly lag 
behind those for other solid tumors, such as NSCLC [13, 
14].
To the best of our knowledge, this is the first report 
on efficacy, safety and predictive biomarkers of pan-HER 
inhibitor in esophageal cancer. In our study, dacomitinib 
showed promising clinical activity with manageable 
toxicity in heavily-pretreated R/M-ESCC. We performed 
next-generation sequencing and nanostring nCounter 
gene expression assay in R/M-ESCC patients treated with 
dacomitinib to identify potential predictive biomarkers 
to this experimental agent. Using this approach, we 
demonstrated that the upregulation of ERBB signaling 
pathway may characterize a subgroup of patients who are 
most likely to benefit from dacomitinib. 
It seemed apparent that the clinical benefit of the 
selective EGFR-TKI (gefitinib, erlotinib) or the EGFR-
specific MoAB (cetuximab) were limited in esophageal 
cancer, with reported ORR of 2.0%-6.6% and PFS of 
1.6-1.8 months [8, 9, 15-18]. However, the efficacy of 
dacomitinib in our study (ORR, 12.5%; PFS, 3.3 months) 
exceeded reports from previous studies with selective 
EGFR-targeted therapies. Furthermore, we observed 
8-week DCR of approximately 72.9% in this population 
with poor prognosis, which could partly be attributed 
to the potential of dacomitinib to simultaneously block 
compensatory signaling from other HER receptors. The 
pan-HER inhibitory effects of dacomitinib might induce 
disease stabilization rather than tumor shrinkage, resulting 
in modest ORR but high DCR. Our results deserves 
attention, given that patients enrolled in our study had 
multiple poor prognostic factors (one third had progressive 
disease after 2 prior chemotherapy regimens and had both 
locoregional and distant diseases). 
Treatment with dacomitinib in heavily pretreated 
R/M-ESCC patients was well tolerated with the frequency 
of AEs comparable to that seen in other studies with 
EGFR-targeted agents. All toxicities reported in our 
study were mostly grade 1-2 and easily manageable with 
supportive care. There has been controversy regarding 
the relationship between acneiform skin rash and clinical 
outcome to EGFR-targeted therapies [19, 20]. However, 
acneiform skin rash were not found to be associated with 
clinical outcomes in our study. 
The EGFR-targeted agents have demonstrated 
only marginal benefit in unselected patients [8, 9, 15-17]. 
Therefore, selection of patients who are most likely to 
respond to EGFR-targeted agents including dacomitinib 
is an important challenge. Conflicting data exist regarding 
the correlation between EGFR expression and response to 
EGFR-targeted agent [8, 9, 21]. Furthermore, conclusions 
that patients with EGFR overexpression derived benefit 
from gefitinib or erlotinib were made based on small 
sample size, which hampers the validity of such analysis. 
In our study, comprehensive biomarker analysis identified 
that the screening for ERBB-related gene expression 
could help identify subgroups most likely benefit from 
dacomitinib in R/M-ESCC. Several studies have shown 
that gene expression signatures could serve as useful 
molecular markers complementary to genetic mutations 
or protein expressions in predicting clinical outcomes 
to targeted therapies. For examples, in addition to 
PIK3CA mutations, gene expression signature involved 
in the PI3K pathway activity may have utility in the 
identification of breast cancer patients likely to benefit 
from a selective PI3K inhibitor therapy [22]. From a 
study in NSCLC, mRNA expression of fibroblast growth 
factor receptor 1 (FGFR1) was the better biomarker of 
FGFR-TKI sensitivity than FGFR1 gene copy number or 
protein expression [23]. Very recently, we demonstrated 
that overexpression of inflammatory genes predicted 
significantly worse survival to dacomitinib in head 
and neck squamous cell carcinoma [11]. Collectively, 
identification of ERBB pathway gene expression as a 
potential biomarker can contribute to the successful 
development of EGFR-targeted therapy in R/M-ESCC. 
Our results need further validation in the future clinical 
trials with EGFR inhibitors in ESCC patients.
Recently, whole exome sequencing studies in ESCC 
have been reported, [24, 25] uncovering recurrent somatic 
mutations in TP53 (60-93%), CDKN2A (3-8%), RB1 
(8-9%), PIK3CA (7-9%) and PTEN (5%). In our study, 
genes involved in cell cycle and apoptosis regulation 
were mutated in 69% of cases by somatic alterations of 
TP53 (61%), CDKN2A (8%) and MLH1 (8%), which 
was comparable to the previous reports. Consistent with 
previous reports [24, 25], we also found mutations in 
PI3K/mTOR pathway including PIK3CA (3%), PTEN 
(3%) and STK11 (3%). Although somatic mutations in 
the EGFR tyrosine kinase domain have been associated 
with dramatic response to EGFR-TKIs in NSCLC, these 
drug-sensitive EGFR mutations are rare in ESCC [8, 9, 
24, 25]. In our study, three patients harbored EGFR exon 
20 mutations (V765M, G810D, C775Y). Interestingly, 
a NSCLC patient with V765M EGFR mutations had 
a partial response to gefitinib [26]. Consistent with this 
report, a case with V765M EGFR mutation in our study 
showed PFS of 4.1 months with 10% of tumor shrinkage. 
The activating mutation (D820E) in exon 17 of KIT 
tyrosine kinase in a patient showing rapid progression 
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within 28 days has been previously reported in imatinib-
resistant gastrointestinal stromal tumors [27, 28].
In conclusion, dacomitinib demonstrated promising 
efficacy in platinum-failed R/M-ESCC. Screening of 
ERBB pathway-related gene expression profiles may 
help identify patients who are most likely to benefit from 
dacomitinib. The value of ERBB gene expression profiling 
in predicting clinical outcome to dacomitinib needs to be 
validated in future randomized trials. 
PATIENTS ANd METhodS
Study design
This was a multicenter, open-label phase II study of 
dacomitinib in patients with recurrent or metastatic ESCC 
(R/M-ESCC) who had progressed on platinum-based 
chemotherapy. The primary objective of this study was 
to assess objective response rate according to Response 
Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 
[29]; secondary end points were to estimate the clinical 
benefit [CB, progression free survival (PFS) ≥ 4 months 
of dacomitinib], duration of responses, disease control 
rate at 8 weeks [8-week DCR; complete response (CR)+ 
partial response (PR)+ stable disease (SD) at 8 weeks), 
PFS, OS, and the tolerability of the treatment. Exploratory 
objectives were to evaluate whether somatic mutation or 
gene expression are correlated with clinical outcomes.
All patients provided signed informed consent and 
the study was conducted in accordance with the Helsinki 
Declaration. The study was approved by the institutional 
review board.
Study population
Patients with pathologically confirmed R/M-ESCC 
not amenable to curative treatment were enrolled. Patients 
were at least age of 18 years, had an Eastern Cooperative 
Oncology Group performance status (ECOG PS) of 0 to 
2, had at least one measurable lesion, had experienced 
treatment failure with one to two prior chemotherapy 
regimens, including platinum-based chemotherapy, 
and had a life expectancy of at least 3 months. Patients 
with prior EGFR inhibitors and ≥ 3 lines of palliative 
chemotherapy for R/M-ESCC were ineligible.
Treatment
Patients received continuous treatment with oral 
dacomitinib 45 mg once daily until disease progression, 
death, or unacceptable adverse events (AEs). Treatment 
cycle was 28 days long. Drug doses withheld and/or 
reduced for intolerable grade 2 or grade 3/4 toxicity. A 
maximum of 2 dose-level reductions were permitted (30 
mg then 15 mg). Dacomitinib administration could be 
interrupted for a maximum of 21 days.
Study assessment
Baseline evaluations included a complete medical 
history, physical and radiologic examinations, complete 
blood count, and biochemistries. Response evaluations 
were defined according to RECIST 1.1 guidelines. 
Radiographic imaging was conducted at week 4, week 
8 and every 8 weeks thereafter until disease progression 
or when clinically indicated. If a patient had a CR or 
PR, a confirmatory evaluation was performed after 4 
weeks. Safety was measured by assessment of physical 
examination, documentation of AEs, laboratory 
measurements on day 1 of each cycle. AEs were graded 
according to the Common Terminology Criteria for 
Adverse Events version 4.0 [30].
Biomarker analyses
Fresh or archival formalin-fixed paraffin embedded 
(FFPE) tumor tissues were collected at baseline for 
biomarker analysis, which included characterization 
of gene expression by Nanostring nCounter® Cancer 
Human Cancer Reference Kit, which is a sensitive 
assay quantifying mRNA transcripts of 230 genes using 
multiplexed, color-coded probes, and somatic mutations 
by Ion Torrent AmpliSeq Cancer Hotspot Panel v2 
(CHPv2), which is a next generation sequencing assay 
detecting 2,800 Catalogue Of Somatic Mutations In 
Cancer (COSMIC) mutations from 50 genes. The sets 
of genes for expression and mutation analysis were 
listed in Supplementary Table 3. These two analytical 
platforms have been previously validated with FFPE 
clinical samples.[31-33] Analysis and normalization of 
the raw Nanostring data was conducted using nSolver 
Analysis Software v1.1 (Nanostring Technologies). 
For a significance analysis of gene expression, gene set 
enrichment analysis (GSEA; http://www.broad.mit.edu/
gsea) were performed with a ratio-of-classes metric for 
gene ranking and 1000 data permutations. Among the 49 
cases, 7 cases had insufficient tumor and 6 and 9 cases 
had insufficient DNA and RNA, respectively. Overall 36 
and 33 cases had successful AmpliSeq and Nanostring 
analyses. 
Statistical rationale for study design and statistical 
analysis
A Fleming’s one-stage design was used to test the 
null hypothesis (P0) with 5% significance level that the 
ORR is ≤ 5% versus the alternative hypothesis (P1) that 
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the ORR is ≥ 15%. Forty-four response-evaluable patients 
were required to provide 80% power to reject P0 when 
the true ORR is 15%. Allowing for 10 % loss to follow-
up rate, it is anticipated that the total sample size is 49. 
PFS was defined from the first day of dacomitinib until the 
first disease progression or death from any cause. OS was 
defined from the first day of dacomitinib to death from any 
cause. For the predictive biomarker analysis, we defined 
clinical benefit (CB) as PFS ≥ 4 months on dacomitinib 
based on the previous results that second-line therapies 
with either cytotoxic agent or EGFR inhibitors in R/M-
ESCC have shown PFS of less than 4 months [16, 34, 35].
PFS and OS were estimated using the Kaplan-Meier 
method, and compared using generalized Wilcoxon test. 
The association of biomarkers with clinical outcomes was 
analyzed using a two-tailed Fisher’s exact test. P-value ≤ 
0.05 was considered significant. 
Experimental study
Proliferation assay: Cell culture and reagents 
ESCC cell line TE2, TE3, and HCE4 were purchased 
from Japanese Cell Resource Center for Biomedical 
Research (Sendai, Japan). All cell lines were cultured 
by RPMI1640 (Invitrogen, Calsbard, CA) added 5% 
bovine serum albumin and penicillin/streptomycin. 
Cells were seeded at 3,000 cells/well in 96 well 
plates and treated with indicated concentrations of 
dacomitinib and MTT reagents [3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazoliumbromide] for 72 hours. 
Cell proliferation was assessed according to manufacture 
instructions. 
Clonogenic assay: Cells were seeded at 3,000 
cells/well in 6 well plate and treated with indicated 
concentrations of dacomitinib for 10 days. Colonies were 
fixed with paraformaldehyde (4%) and stained crystal 
violet (0.05% w/v) for 30 min Western blot analysis: 
Cells were treated with indicated concentrations of 
dacomitinib and lysed in Cell lysis buffer (Cell signaling, 
Danvers, MA) containing protease inhibitor cocktail 
(Roch Diagnostics, Mannheim, Germany). Protein 
content was resolved by SDS-PAGE, and was transferred 
to nitrocellulose membranes (Millipore, Temecula, CA). 
p-EGFR (Y1068), EGFR, p-AKT(S473), AKT, p-ERK 
(T202/Y204), and ERK secondary antibodies were 
purchased from Cell Signaling Technology (Beverly, MA, 
USA) and β-actin from Santa Cruz biotechnology (Santa 
Cruz, CA, USA).
Quantitative real-time PCR: Total RNA was 
purified from cells using RNeasy mini prep kits (Qiagen). 
cDNA was prepared from 2 mg total RNA using the 
SuperScript first-strand synthesis system (Invitrogen Life 
Technologies, Inc.). Differential RNA levels were assessed 
using Taqman gene expression assay (Life Technologies). 
Quantitative PCR reactions were performed on a VIIA7 
Real-Time PCR system and analysed using VIIA7 
software (Life Technologies).
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